Ipamorelin + CJC No DAC Research: GHS-R and GHRH Pathway Models

Two Peptides, Two Receptor Systems

Ipamorelin is a pentapeptide growth-hormone secretagogue studied for activity at the GHS-R1a/ghrelin-receptor system. The CJC No-DAC component is intended to model the GHRH-receptor pathway. These receptor systems are distinct upstream mechanisms that can converge on pituitary growth-hormone release.

Ipamorelin and GHS-R1a

Classic pharmacology work identified ipamorelin as a potent GH secretagogue with greater selectivity for GH release than GHRP-2 and GHRP-6 in the tested animal models. See Ipamorelin, the first selective growth hormone secretagogue.

What Does “CJC No DAC” Mean?

This naming area is frequently confused. The peer-reviewed compound called CJC-1295 in the original development program included an albumin-binding Drug Affinity Complex (DAC). That DAC-bearing molecule was engineered for prolonged circulation. The product commonly sold as “CJC-1295 No DAC” instead refers to a modified GHRH(1-29)-type sequence without that albumin-binding extension.

Because the molecules differ, the multi-day pharmacokinetic findings from classic DAC CJC-1295 studies should not be automatically assigned to the No-DAC material. A 2026 evidence review of performance-enhancing peptides notes that the No-DAC form remains poorly characterized in controlled human literature and that many claims are extrapolated from related GHRH compounds.

What the DAC CJC-1295 Literature Actually Shows

The original long-acting CJC-1295 studies are still useful for understanding GHRH-receptor biology and the role of albumin binding, as long as the distinction is explicit. Published work reported prolonged GH and IGF-1 responses with the DAC-bearing analogue in healthy adults. See Prolonged stimulation of GH and IGF-I secretion by CJC-1295.

Additional work found preserved GH pulsatility during continuous stimulation with the long-acting DAC form. See Pulsatile secretion of GH persists during continuous stimulation by CJC-1295. These results describe the DAC molecule, not the No-DAC product.

Why a Dual-Pathway Blend Is Scientifically Interesting

A combined research design can ask whether GHS-R1a and GHRH-receptor signaling are additive, synergistic, redundant, or temporally distinct in a chosen model. Useful endpoints include receptor-specific second messengers, GH secretory patterns, desensitization, and downstream IGF-related signals.

Related Research Comparisons

For the GHRH side, compare with Sermorelin or Tesamorelin. For the GHS-R side, compare with GHRP-2 and GHRP-6.

Experimental Design Considerations

• Measure pathway-specific signals rather than only a shared downstream endpoint.
• Keep No-DAC and DAC CJC literature clearly separated.
• Define sampling intervals carefully when comparing peptides with different exposure profiles.
• Include single-component controls when studying a blend.
• Document receptor expression and baseline endocrine state.

Evidence Limits

Direct controlled human evidence for the No-DAC compound is limited. Claims should therefore remain anchored to receptor pharmacology, in-vitro/preclinical evidence, or clearly identified extrapolation from related GHRH analogues.

IPAM + CJC No DAC FAQ

Is CJC No DAC identical to classic CJC-1295?

No. The classic peer-reviewed CJC-1295 program used an albumin-binding DAC extension. The common “No DAC” material lacks that feature.

What receptor does ipamorelin primarily model?

The GHS-R1a/ghrelin-receptor system.

What receptor does the No-DAC GHRH analogue primarily model?

The GHRH receptor.

Browse the Research Journal for related endocrine articles.

Research Use Only. Not intended for human or veterinary use.